Germline CDH1 mutations in bilateral lobular carcinoma in situ
暂无分享,去创建一个
M. Simpson | S. Pinder | E. Sawyer | I. Tomlinson | R. Trembath | R. Roylance | P. Gorman | K. Kohut | A. Hanby | C. Petridis | V. Shah | M. Caneppele | I. Shinomiya | M. Troy | I. Tomlinson | Vandna Shah | Kelly Kohut | Michele Caneppele | Patricia Gorman | Sarah E Pinder | Andrew M. Hanby | Michael A. Simpson | P. Gorman | A. Hanby
[1] A. Sézeur,et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study , 2013, Journal of Medical Genetics.
[2] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[3] Janice S. Sung,et al. Screening breast MR imaging in women with a history of lobular carcinoma in situ. , 2011, Radiology.
[4] Y. Bignon,et al. Germline mutations of the E‐cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer , 2011, Cancer.
[5] O. Olopade,et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers , 2010, Journal of Medical Genetics.
[6] C. Caldas,et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research , 2010, Journal of Medical Genetics.
[7] Yoko Ito,et al. Mechanisms and sequelae of E‐cadherin silencing in hereditary diffuse gastric cancer , 2008, The Journal of pathology.
[8] P. Miron,et al. Germline E-cadherin mutations in familial lobular breast cancer , 2007, Journal of Medical Genetics.
[9] B. Fernandez,et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.
[10] E. Morris,et al. Results of MRI Screening for Breast Cancer in High-Risk Patients with LCIS and Atypical Hyperplasia , 2007, Annals of Surgical Oncology.
[11] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[12] R. Severson,et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Huntsman,et al. Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management , 2005, Clinical Cancer Research.
[14] P. Bult,et al. The Role of MRI in Invasive Lobular Carcinoma , 2004, Breast Cancer Research and Treatment.
[15] W. Foulkes,et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.
[16] Norman Wolmark,et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project , 2004, Cancer.
[17] C Caldas,et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.
[18] R. Roylance,et al. Multiple ways of silencing E‐cadherin gene expression in lobular carcinoma of the breast , 2001, International journal of cancer.
[19] S. Seal,et al. Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene , 2000, British Journal of Cancer.
[20] Anthony E. Reeve,et al. E-cadherin germline mutations in familial gastric cancer , 1998, Nature.
[21] W. Thompson,et al. Relationship between breast histopathology and family history of breast cancer , 1993, Cancer.